Моксифлоксацин в ступенчатой терапии (внутривенно и внутрь) осложненных абдоминальных инфекций: результаты исследования и обзор литературы

1. Meakins JL, Solomkin JS, Allo MD et al. A proposed classification of intra-abdominal infections: stratification of etiology and risk for future therapeutic trials. Arch Surg 1984; 119: 1372–8.
2. Solomkin JS, Mazuski JE, Baron EJ et al. Guidelines for the Selection of Anti-infective Agents for Complicated Intra-abdominal Infections. Clin Infect Dis 2003; 37: 997–1005.
3. Finegold SM. Abdominal and perineal infections. In: Finegold SM, ed. Anaerobic bacteria in human disease. New York: Academic Press, 1977; 257–313.
4. Gorbach SL, Thadepalli H, Norsen J et al. Anaerobic microorganisms in intra-abdominal infections. In: Balows A, de Haan RM, Dowell VR, et al., eds. Anaerobic bacteria: role in disease. Springfield, IL: Charles C Thomas, 1974; 399–407.
5. Altemeier WA. The bacterial flora of acute perforated appendicitis with peritonitis. Ann Surg 1938; 107: 517–28.
6. Swenson RM, Lorber B, Michaelson TC et al. The bacteriology of intra-abdominal infections. Arch Surg 1974; 109: 389–98.
7. Bennion RS, Thompson JL, Baron EL et al. Gangrenous and perforated appendicitis with peritonitis: treatment and bacteriology. Clin Ther 1990; 12 (Suppl. C): 31–44.
8. Mazuski JE, Sawyer RG, Nathens AB et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: an executive summary. Surg Infections 2002; 3 (3): 161–73.
9. Soussy CJ, Nguyen J, Goldstein F et al. In vitro antibacterial activity of moxifloxacin against hospital isolates: a multicentre study. Clin Microbiol Infect 2003; 9 (10): 997–1005.
10. Ambler JE, Choudhri SH, Haverstock D et al. Moxifloxacin in vitro activity against non-pneumococcal streptococci isolated from six recent clinical studies [abstr P1301]. 16th European Congress of Clinical Microbiology Infectious Diseases, April 1–4, 2006. Nice, France.
11. Edmistone CE, Krepel JK, Seabrook GR et al. In Vitro Activities of Moxifloxacin against 900 Aerobic and Anaerobic Surgical Isolates from Patients with Intra-Abdominal and Diabetic Foot Infections. Antimicrob Agents Chemother 2004; 48: 1012–6.
12. Thadepalli H, Chuah SK, Gollapudi S. Therapeutic efficacy of moxifloxacin, a new quinolone, in the treatment of experimental intra-abdominal abscesses induced by Bacteroides fragilis in mice. Chemotherapy 2004; 50 (2): 76–80.
13. Hermsen ED, Hovde LB, Sprandel KA et al. Moxifloxacin Monotherapy against a Mixed Infection of Escherichia coli and Bacteroides fragilis in an In Vitro Pharmacodynamic Model. Antimicrob Agents Chemother 2005; 49: 685–9.
14. Schaumann R, Blatz R, Beer J, Ackermann G, Rodloff AC. Effect of moxifloxacin versus imipenem/cilastatin treatment on the mortality of mice infected intravenously with different strains of Bacteroides fragilis and Escherichia coli. J Antimicrob Chemother 2004; 53 (2): 318–24.
15. Stass H, Rink AD, Delesen H et al. Pharmacokinetics of moxifloxacin in tissues of the CI-tract [Abstr O359]. 16th European Congress of Clinical Microbiology Infectious Diseases, April 1–4, 2006. Nice, France.
16. Stass H, Rink AD, Delesen H et al. Pharmacokinetics and peritoneal penetration of moxifloxacin in peritonitis. J Antimicrob Chemother 2006; 58: 693–6.
17. Schwab D, Grauer M, Hahn EG, Muhldorfer S. Biliary secretion of moxifloxacin in obstructive cholangitis and the non-obstructed biliary tract. Aliment Pharmacol Ther 2005; 22 (5): 417–22.
18. Barth J, J?ger D, Mundkowski R et al. Singleand multipledose pharmacokinetics of intravenous moxifloxacin in patients with severe hepatic impairment. J Antimicrob Chemother 2008; 62 (3): 575–8.
19. Rink AD, Stass H, Delesen H et al. Pharmacokinetics and tissue penetration of moxifloxacin in intervention therapy for intraabdominal abscess. Clin Drug Investig 2008; 28 (2): 71–9.
20. Malangoni M, Song J, Choudhri S et al. Sequential IV/PO moxifloxacin versus IN piperacillin/tazobactam +/PO amoxicillin/clavulanate  for  treatment  of  complicated  intra-abdominal infections [Abstr 402710]. 44th Interscience Conf Antimicrob Agents Chemother, Oct 30 – Nov 2, 2004. Washington, DC.